Academic Research Consortium (ARC-1) - Coronary

• Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions. Circulation 2007; 115:
2344-2351 
https://pubmed.ncbi.nlm.nih.gov/17470709/

Independence of clinical events committees: A consensus statement from clinical research organizations.

Reference: Am Heart J. 2022 Jun; 248:120-129.

Defining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology.

Reference: EuroIntervention. 2020 Jan 17;15(13):1190-1198.

Defining Staged Procedures for Percutaneous Coronary Intervention Trials: A Guidance Document.

Reference: JACC Cardiovasc Interv. 2018 May 14;11(9):823-832.

Limited usefulness of the modified Academic Research Consortium stent thrombosis definition for clinical trials.

Reference: JACC Cardiovasc Interv. 2011 Oct;4(10):1151; author reply 1151-2.

Identifying stent thrombosis, a critical appraisal of the academic research consortium (ARC) consensus definitions: a lighthouse and as a toe in the water.

Reference: EuroIntervention. 2008 Aug;4 Suppl C:C39-44.

Chronic Total Occlusions Academic Research Consortium 1 (CTO-ARC)

Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations.

Reference: Circulation. 2021 Feb 2;143(5):479-500.

Be the first one to share a relevant reference

Relevant references are those validating definitions, studying clinical outcomes on the basis of standardized definitions, comparing different definitions, or describing advantages (or challenges) in utilizing the definitions. Please submit the reference of the published document through our contact form.
https://www.academicresearchconsortium.com/contact/

Bifurcations Academic Research Consortium

• Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations.

Reference: J Am Coll Cardiol. 2022 Jul 5;80(1):63-88.

• Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations.

Reference: EuroIntervention. 2022 May 18;EIJ-E-22-00018.

Be the first one to share a relevant reference

Relevant references are those validating definitions, studying clinical outcomes on the basis of standardized definitions, comparing different definitions, or describing advantages (or challenges) in utilizing the definitions. Please submit the reference of the published document through our contact form.

https://www.academicresearchconsortium.com/contact/

Bleeding Academic Research Consortium (BARC-1)

Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium.

Reference: Circulation 2011; 123: 2736-2747

Assessing bleeding in acute coronary syndrome using the Bleeding Academic Research Consortium definition.

Reference: J Cardiovasc Med (Hagerstown). 2019 Dec;20(12):818-824.

Clinical utility of new bleeding criteria: a prospective study of evaluation for the Bleeding Academic Research Consortium definition of bleeding in patients undergoing percutaneous coronary intervention.

Reference: J Cardiol. 2015 Apr;65(4):324-9.

The prognostic value of BARC-defined bleeding complications in ST-segment elevation myocardial infarction: a comparison with the TIMI, GUSTO, and ISTH bleeding classifications.

Reference: J Am Coll Cardiol. 2014 May 13;63(18):1866-75.

Prognostic implications of bleeding measured by Bleeding Academic Research Consortium (BARC) categorisation in patients undergoing primary percutaneous coronary intervention

Reference: Heart. 2014 Jan;100(2):146-52.

Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention

Reference: Circulation. 2012 Mar 20;125(11):1424-31.

Editorial: do we need another bleeding definition? What does the Bleeding Academic Research Consortium definition have to offer?

Reference: Curr Opin Cardiol. 2011 Jul;26(4):275-8.

High Bleeding Risk Academic Research Consortium (ARC-HBR-1)

• Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk (ARC-HBR-1).
Reference: Eur Heart J. 2019 Aug 14;40(31):2632-2653.

• Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention (ARC-HBR-1).
Reference: Circulation. 2019 Jul 16;140(3):240-261.

Association between the number of academic research consortium for high bleeding risk (ARC-HBR) criteria and clinical outcomes in patients with acute coronary syndrome.

Reference: J Cardiol. 2023 Jan 19:S0914-5087(23)00003-5.

Validation of the Academic Research Consortium High Bleeding Risk (ARC-HBR) criteria in patients undergoing peripheral endovascular interventions.

Reference: EuroIntervention. 2022 Dec 29:EIJ-D-22-00475.

ARC-HBR criteria and TAVR: not all high bleeding risk patients look alike.

Reference: EuroIntervention. 2022 Aug 19;18(6):448-449.

Comparison of original and modified Academic Research Consortium for High Bleeding Risk definitions in real-world practice.

Reference: J Cardiol. 2022 Aug;80(2):155-161.

Ischemic and Bleeding Outcomes According to the Academic Research Consortium High Bleeding Risk Criteria in All Comers Treated by Percutaneous Coronary Interventions.

Reference: Front Cardiovasc Med. 2021 Dec 2;8:620354.

Validation of the academic research consortium high bleeding risk criteria in patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis of 10 studies and 67,862 patients.

Reference: Int J Cardiol. 2022 Jan 15;347:8-15.

Practical Assessment of the Tradeoff between Fatal Bleeding and Coronary Thrombotic Risks using the Academic Research Consortium for High Bleeding Risk Criteria.

Reference: J Atheroscler Thromb. 2022 Aug 1;29(8):1236-1248.

Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction.

Reference: J Thromb Thrombolysis. 2022 Jan;53(1):20-29.

Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria.

Reference: J Am Heart Assoc. 2021 Jun 15;10(12):e021965.

Applicability of the Academic Research Consortium for High Bleeding Risk in acute coronary syndrome undergoing percutaneous coronary intervention.

Reference: Rev Esp Cardiol (Engl Ed). 2022 May;75(5):375-383.

Academic Research Consortium Definition of High Bleeding Risk in Clinical Practice - Validation and Beyond.

Reference: Circ J. 2021 May 25;85(6):806-807.

Prevalence of the Academic Research Consortium high bleeding risk criteria in patients undergoing endovascular therapy for peripheral artery disease in lower extremities.

Reference: Heart Vessels. 2021 Sep;36(9):1350-1358.

Validation and Additive Predictive Value of the Academic Research Consortium-High Bleeding Risk Criteria in Older Adults.

Reference: Thromb Haemost. 2021 Sep;121(9):1255-1257.

Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk.

Reference: Eur Heart J. 2020 Oct 7;41(38):3743-3749.

Prevalence of the Academic Research Consortium for High Bleeding Risk Criteria and Prognostic Value of a Simplified Definition.

Reference: Circ J. 2020 Aug 25;84(9):1560-1567.

Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients.

Reference: J Am Coll Cardiol. 2020 Jun 2;75(21):2711-2722.

Validation of Standardization: Testing the Academic Research Consortium High Bleeding Risk Criteria.

Reference: Circ Cardiovasc Interv. 2019 Nov;12(11):e008569.

Valve Academic Research Consortium 1 (VARC-1)

• Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: A Consensus Report From the Valve Academic Research Consortium.
Reference: European Heart Journal 2011 Jan; 32(2): 205-217.

• Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: A Consensus Report From the Valve Academic Research Consortium.
Reference: J Am Coll Cardiol. 2011 Jan 18;57(3):253-69.

Valve Academic Research Consortium 3 (VARC-3)

• Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research.
Reference: Eur Heart J. 2021 May 14;42(19):1825-1857.

• Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research.
Reference: J Am Coll Cardiol. 2021 Jun 1;77(21):2717-2746.

Durability of a bovine pericardial aortic bioprosthesis based on Valve Academic Research Consortium-3 echocardiographic criteria.

Reference: JTCVS Open. 2022 May 29;11:72-80.

The Deployment of Valve Academic Research Consortium 3 (VARC-3): New Endpoints, Broader Definitions, and Plenty of Unanswered Questions.

Reference: J Cardiothorac Vasc Anesth. 2021 Dec;35(12):3463-3466.

Independent Risk Factors Contributing to Acute Kidney Injury According to Updated Valve Academic Research Consortium-2 Criteria After Transcatheter Aortic Valve Implantation: A Meta-analysis and Meta-regression of 13 Studies.

Reference: J Cardiothorac Vasc Anesth. 2017 Jun;31(3):816-826.

Validation of the Valve Academic Research Consortium Bleeding Definition in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation.

Reference: J Am Heart Assoc. 2015 Sep 25;4(10):e002135.

Vascular complications after transcatheter aortic valve implantation and their association with mortality reevaluated by the valve academic research consortium definitions.

Reference: Am J Cardiol. 2015 Jan 1;115(1):100-6.

Usefulness of updated valve academic research consortium-2 criteria for acute kidney injury following transcatheter aortic valve implantation.

Reference: Am J Cardiol. 2013 Dec 1;112(11):1807-11.

Incidence, predictors, and prognosis of acute kidney injury after transcatheter aortic valve implantation: a summary of contemporary studies using Valve Academic Research Consortium definitions.

Reference: Int J Cardiol. 2013 Sep 30;168(2):1631-5.

Predictors and outcomes after transcatheter aortic valve implantation using different approaches according to the valve academic research consortium definitions.

Reference: Catheter Cardiovasc Interv. 2013 Oct 1;82(4):640-52.

Building on the shoulders of giants: the Valve Academic Research Consortium (VARC) initiative towards a global framework to guide valvular heart disease trials.

Reference: EuroIntervention. 2012 Sep;8 Suppl Q:Q12-4.

Transcatheter aortic valve implantation (TAVI) outcome according to standardized endpoint definitions by the Valve Academic Research Consortium (VARC).

Reference: J Invasive Cardiol. 2011 Aug;23(8):307-12.

In-hospital complications after transcatheter aortic valve implantation revisited according to the Valve Academic Research Consortium definitions.

Reference: Catheter Cardiovasc Interv. 2011 Sep 1;78(3):457-67.

Clinical endpoints in transcatheter aortic valve implantation: a call to ARC for standardised definitions.

Reference: EuroIntervention. 2009 May;5(1):29-31.

Mitral Academic Research Consortium (MVARC-1-Part 1): Design Principles

• Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles A Consensus Document From the Mitral Valve Academic Research Consortium (MVARC-1 Part 1, 2015).
Reference: Eur Heart J. 2015 Aug 1;36(29):1851-77

• Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles A Consensus Document From the Mitral Valve Academic Research Consortium (MVARC-1 Part 1, 2015).
Reference: J Am Coll Cardiol. 2015 Jul 21;66(3):278-307.

Percutaneous Mitral Valve Repair With the MitraClip in Primary Compared With Secondary Mitral Valve Regurgitation Using the Mitral Valve Academic Research Consortium Criteria.

Reference: J Invasive Cardiol. 2017 Apr;29(4):145-150.

Mitral Valve Academic Research Consortium Consensus Report: The U.S. Food and Drug Administration Perspective.

Reference: J Am Coll Cardiol. 2015 Jul 21;66(3):322-323.

Paravalvular leaks Academic Research Consortium (PVL-ARC-1)

Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis: An Expert Statement (PVL-ARC-1, 2017).
Reference: J Am Coll Cardiol. 2017 Apr 25;69(16):2067-2087.

Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis (PVL-ARC-1, 2017).
Reference: Eur Heart J. 2018 Apr 14;39(15):1224-1245.

Be the first one to share a relevant reference

Relevant references are those validating definitions, studying clinical outcomes on the basis of standardized definitions, comparing different definitions, or describing advantages (or challenges) in utilizing the definitions.

Please submit the reference of the published document through our contact form.

Neurological events Academic Research Consortium (Neuro-ARC-1)

• Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative (Neuro-ARC-1, 2017).
Reference: Eur Heart J. 2018 May 14;39(19):1687-1697.

• Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative (Neuro-ARC-1, 2017).
Reference: J Am Coll Cardiol. 2017 Apr 25;69(16):2067-2087.

Be the first one to share a relevant reference

Relevant references are those validating definitions, studying clinical outcomes on the basis of standardized definitions, comparing different definitions, or describing advantages (or challenges) in utilizing the definitions.

Please submit the reference of the published document through our contact form.

Peripheral Academic Research Consortium 1 (PARC-1)

Evaluation and Treatment of Patients With Lower Extremity Peripheral Artery Disease: Consensus Definitions From Peripheral Academic Research Consortium (PARC).
Reference: J Am Coll Cardiol. 2015;65(9):931-941.

Be the first one to share a relevant reference

Relevant references are those validating definitions, studying clinical outcomes on the basis of standardized definitions, comparing different definitions, or describing advantages (or challenges) in utilizing the definitions.

Please submit the reference of the published document through our contact form.

Hypertension Academic Research Consortium 1 (HARC-1)

Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium.
Reference: Circulation. 2022 Mar 15;145(11):847-863.

Be the first one to share a relevant reference

Relevant references are those validating definitions, studying clinical outcomes on the basis of standardized definitions, comparing different definitions, or describing advantages (or challenges) in utilizing the definitions. Please submit the reference of the published document through our contact form.

Hypertension Academic Research Consortium 1 (HF-ARC-1)

• Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium.
Reference: JACC Heart Fail. 2020 Dec;8(12):961-972.

• Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium.
Reference: Eur J Heart Fail. 2020 Dec;22(12):2175-2186.

Be the first one to share a relevant reference

Relevant references are those validating definitions, studying clinical outcomes on the basis of standardized definitions, comparing different definitions, or describing advantages (or challenges) in utilizing the definitions. Please submit the reference of the published document through our contact form.

Mechanical Circulatory Support Academic Research Consortium 1 (MCS-ARC-1)

Updated definitions of adverse events for trials and registries of mechanical circulatory support: A consensus statement of the mechanical circulatory support academic research consortium.
Reference: J Heart Lung Transplant. 2020 Aug;39(8):735-750.

Be the first one to share a relevant reference

Relevant references are those validating definitions, studying clinical outcomes on the basis of standardized definitions, comparing different definitions, or describing advantages (or challenges) in utilizing the definitions. Please submit the reference of the published document through our contact form.

Non-adherence Academic Research Consortium (NARC-1)

Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC-1, 2018).
Reference: Eur Heart J. 2018 Jul 9.

Self-reported non-adherence to P2Y12 inhibitors in patients undergoing percutaneous coronary intervention: Application of the medication non-adherence academic research consortium classification.

Reference: PLoS One. 2022 Feb 16;17(2):e0263180.

Drug-coated Balloons Academic Research Consortium (DCB-ARC-1)

• Definitions and standardized endpoints for the use of drug-coated balloon in coronary artery disease: consensus document of the Drug Coated Balloon Academic Research Consortium. EuroIntervention. 2025 Apr 24;21(19):e1116-e1136.
PubMed link: https://pubmed.ncbi.nlm.nih.gov/40272160/

• Indications for Use of Drug-Coated Balloons in Coronary Intervention: Academic Research Consortium Position Statement J Am Coll Cardiol. 2025 Oct 14;86(15):1170-1202.
PubMed link: https://pubmed.ncbi.nlm.nih.gov/41062231/

Tricuspid Academic Research Consortium 1 (TVARC-1)

Tricuspid Valve Academic Research Consortium Definitions for Tricuspid Regurgitation and Trial Endpoints.
Reference: J Am Coll Cardiol. 2023 Oct 24;82(17):1711-1735. 
https://pubmed.ncbi.nlm.nih.gov/37804294/

Tricuspid Academic Research Consortium 1 (TVARC-1)

Tricuspid Valve Academic Research Consortium Definitions for Tricuspid Regurgitation and Trial Endpoints.
Reference: Eur Heart J. 2023 Nov 14;44(43):4508-4532.
https://pubmed.ncbi.nlm.nih.gov/37793121/

Shock Academic Research Consortium 1 (SHARC-1)

Circulation. 2023 Oct 3;148(14):1113-1126.
https://pubmed.ncbi.nlm.nih.gov/37782695/

ECMO Core Elements Needed for Trials Regulation And quality of Life (ECMO-CENTRAL) ARC

• Definitions of adverse events associated with extracorporeal membrane oxygenation in children: results of an international Delphi process from the ECMO-CENTRAL ARC. Lancet Child Adolesc Health. 2024 Oct;8(10):773-780
https://pubmed.ncbi.nlm.nih.gov/39299748/

Pediatric mechanical circulatory support

• ACTION-ARC Pediatric and Adult Congenital Heart Disease Ventricular Assist Device Adverse Event Definitions-2023

https://pubmed.ncbi.nlm.nih.gov/39330959/

Left Atrial Appendage Academic Research Consortium - LAARC

Standardized endpoint definitions for trials of transcatheter left atrial appendage closure: a consensus from the Left Atrial Appendage Academic Research Consortium.

Reference: Eur Heart J. 2026 Jul 9. Epub ahead of print.